<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MORINE, YUJI</style></author><author><style face="normal" font="default" size="100%">IKEMOTO, TETSUYA</style></author><author><style face="normal" font="default" size="100%">IWAHASHI, SHUICHI</style></author><author><style face="normal" font="default" size="100%">SAITO, YU</style></author><author><style face="normal" font="default" size="100%">YAMADA, SHINICHIRO</style></author><author><style face="normal" font="default" size="100%">TAKASU, CHIE</style></author><author><style face="normal" font="default" size="100%">HIGASHIJIMA, JUN</style></author><author><style face="normal" font="default" size="100%">IMURA, SATORU</style></author><author><style face="normal" font="default" size="100%">SHIMADA, MITSUO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5089-5096</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.13703</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">9</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). Patients and Methods: A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. Results: The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter × number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). Conclusion: FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit.</style></abstract></record></records></xml>